RxDoctor Payments Data

Kevin Gaffney, MD

Neurology · Shenandoah, TXNPI 1972506426

Payments from drug & device makers

$34,957in general payments, 2019–2025

Across 696 payments — averaging $50.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$8K
  • Sanofi$8K
  • Teva Pharmaceuticals USA, Inc.$8K
  • Novartis$1K
  • Inspire Medical Systems, Inc.$987
  • TG Therapeutics, Inc.$947
  • plus $9K from 54 others

What the payments were for

  • Consulting fees$7,48021%
  • Speaking & faculty fees$10,47530%
  • Travel & lodging$1,7385%
  • Food & beverage$15,00943%
  • Education$2551%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)125$7,888
Sanofi15$7,608
Teva Pharmaceuticals USA, Inc.23$7,601
Novartis99$1,309
Inspire Medical Systems, Inc.45$987
TG Therapeutics, Inc.11$947
EMD Serono, Inc.35$858
Eisai Inc.26$621
Harmony Biosciences LLC20$535
Neurocrine Biosciences, Inc.20$495
Biohaven Pharmaceutical Holding Company Ltd.19$405
Pfizer18$389
AstraZeneca(2 entities)14$368
Genentech USA, Inc.14$367
Lilly USA, LLC22$365
Jazz Pharmaceuticals Inc.9$272
UCB, Inc.12$271
Biogen14$271
Axsome Therapeutics, Inc.11$248
Argenx US, Inc.8$239
Amgen6$237
Grifols USA, LLC10$236
Bristol Myers Squibb9$192
Takeda Pharmaceuticals U.S.A., Inc.7$172
Lundbeck LLC10$169
Otsuka America Pharmaceutical, Inc.7$163
Merz Pharmaceuticals, LLC7$163
Acadia Pharmaceuticals Inc9$160
SK Life Science, Inc.7$153
Genentech, Inc.3$144
Supernus Pharmaceuticals, Inc.5$107
GE HealthCare4$79
Aucta Pharmaceuticals, Inc.9$74
Acorda Therapeutics, Inc3$69
Livanova USA, Inc.3$54
Avion Pharmaceuticals3$50
E.r. Squibb & Sons, L.L.C.3$48
Azurity Pharmaceuticals, Inc.2$47
Impel Pharmaceuticals Inc.3$47
MDD US Operations, LLC2$38
Amneal Pharmaceuticals LLC2$36
Noctrix Health, Inc.1$35
Itamar Medical Inc1$33
Corium, LLC1$31
GRT US Holding, Inc.2$30
Alnylam Pharmaceuticals Inc.1$26
Biohaven Pharmaceuticals, Inc.1$24
Boston Scientific1$24
Amylyx Pharmaceuticals, Inc.1$24
Johnson & Johnson1$23
Avanir Pharmaceuticals, Inc.1$23
Catalyst Pharmaceuticals, Inc.1$23
Impel Pharmaceuticals LLC1$22
Merz North America, Inc.1$22
Cycle Pharmaceuticals Inc1$21
Otsuka Pharmaceutical Development & Commercialization, Inc.1$21
Medtronic1$20
Vanda Pharmaceuticals Inc.1$19
ZOLL Respicardia, Inc.1$17
Strongbridge US Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,957 in reported general payments places this provider in the 80th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$796,658
Medicare patients
706
Services billed
25,239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AubagioTeriflunomide12$110,351
FingolimodFingolimod Hcl28$99,207
Aimovig AutoinjectorErenumab-Aooe28$52,125
Emgality PenGalcanezumab-Gnlm25$36,459
GlatopaGlatiramer Acetate19$27,336
QuliptaAtogepant21$25,959
RytaryCarbidopa/Levodopa13$22,357
Dalfampridine ErDalfampridine31$21,990
Nurtec OdtRimegepant Sulfate21$21,355
BotoxOnabotulinumtoxina14$15,195
Rasagiline Mesylate82$14,244
Dimethyl Fumarate11$9,125
Levetiracetam140$8,675
Gabapentin336$6,913
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone20$6,116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiAubagio$7,608$110,35112 claims
AbbVieQulipta, Botox$7,888$41,15335 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$36$23,81734 claims
PfizerNurtec Odt$389$21,35521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,246 neurology providers in Texas.

Other neurology in Shenandoah

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →